EU Science Hub

The Therapeutic Potential of Anti-HER2 2Rs15d Nanobody Labeled with 225Ac – an In Vitro and In Vivo Evaluation


Human Epidermal Growth Factor Receptor type 2 (HER2) is overexpressed in numerous carcinomas and is often associated with a higher recurrence rate and a shorter time to relapse. Nanobodies (Nbs) are the smallest antibody-derived fragments with beneficial pharmacokinetic properties for molecular imaging and targeted radionuclide therapy (TRT). HER2-targeting nanobodies are very attractive vectors for TRT, especially when labeled with α-particle emitters, which provide highly lethal and localized radiation to targeted cells with minimal exposure to surrounding healthy tissues. The aim of this study was to evaluate the therapeutic potential of the anti-HER2 Nb 2Rs15d labeled with 225Ac.